Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCELNASDAQ:MEIPNASDAQ:NXTCNASDAQ:RAIN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCELAtreca$0.09$0.09$0.05▼$1.20$3.57M1.034.61 million shsN/AMEIPMEI Pharma$2.28+3.6%$2.13$1.46▼$4.10N/A0.1643,161 shs4,163 shsNXTCNextCure$0.47-0.9%$0.47$0.22▼$1.82$13.18M1.07125,467 shs118,591 shsRAINRain Enhancement Technologies Holdco$2.87-0.3%$1.21$0.82▼$11.32$21.77M-0.2213,390 shs21,608 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCELAtreca0.00%0.00%0.00%0.00%0.00%MEIPMEI Pharma+3.59%+1.06%+5.75%-1.77%-18.02%NXTCNextCure-0.91%+3.15%-8.29%-12.38%-72.28%RAINRain Enhancement Technologies Holdco-0.35%-12.31%-31.59%+48.70%+137.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCELAtrecaN/AN/AN/AN/AN/AN/AN/AN/AMEIPMEI Pharma1.5585 of 5 stars0.03.00.04.10.00.81.3NXTCNextCure4.5008 of 5 stars3.55.00.04.31.21.71.3RAINRain Enhancement Technologies HoldcoN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCELAtreca 0.00N/AN/AN/AMEIPMEI Pharma 2.00HoldN/AN/ANXTCNextCure 3.00Buy$3.50651.56% UpsideRAINRain Enhancement Technologies Holdco 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCELAtrecaN/AN/AN/AN/A$2.01 per shareN/AMEIPMEI Pharma$65.30MN/A$6.16 per share0.37$4.96 per shareN/ANXTCNextCureN/AN/AN/AN/A$2.34 per shareN/ARAINRain Enhancement Technologies HoldcoN/AN/AN/AN/A($0.96) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCELAtreca-$97.16M-$2.50N/AN/AN/AN/A-157.90%-71.39%N/AMEIPMEI Pharma$17.78M-$4.75N/AN/AN/AN/A-77.00%-64.79%N/ANXTCNextCure-$55.65M-$1.76N/AN/AN/AN/A-70.16%-58.10%7/30/2025 (Estimated)RAINRain Enhancement Technologies Holdco-$4.53MN/A0.00∞N/AN/AN/A-43.86%N/ALatest NXTC, MEIP, RAIN, and BCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025RAINRain Enhancement Technologies HoldcoN/A-$0.20N/A-$0.20N/AN/A5/13/2025Q3 2025MEIPMEI PharmaN/A-$0.39N/A-$0.39N/AN/A5/1/2025Q1 2025NXTCNextCure-$0.40-$0.39+$0.01-$0.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCELAtrecaN/AN/AN/AN/AN/AMEIPMEI PharmaN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ARAINRain Enhancement Technologies HoldcoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCELAtrecaN/A1.581.58MEIPMEI PharmaN/A16.7816.78NXTCNextCureN/A10.2610.26RAINRain Enhancement Technologies HoldcoN/A0.090.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCELAtreca37.47%MEIPMEI Pharma52.38%NXTCNextCure42.65%RAINRain Enhancement Technologies Holdco25.79%Insider OwnershipCompanyInsider OwnershipBCELAtreca11.30%MEIPMEI Pharma3.12%NXTCNextCure13.30%RAINRain Enhancement Technologies Holdco47.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCELAtreca13039.62 million35.15 millionOptionableMEIPMEI Pharma100N/AN/AOptionableNXTCNextCure9028.05 million24.32 millionOptionableRAINRain Enhancement Technologies Holdco637.59 million3.97 millionNo DataNXTC, MEIP, RAIN, and BCEL HeadlinesRecent News About These CompaniesRiders brave the rain to ride for a cause during Cruise for CancerJune 9, 2025 | msn.com'AI Can Detect Cancer, But Bengaluru Still Can’t Handle Rain?' Investor's Viral Rant Sparks DebateMay 21, 2025 | msn.comThousands brave rainy weather for Race For Hope to fund brain cancer researchMay 9, 2025 | msn.comPart of Horn Island is up for sale, listed for $25MMay 9, 2025 | wlox.com10-year-old cancer survivor rings bell, throws first pitch at Space Cowboys gameMay 3, 2025 | msn.comLead singer for popular U.K. rock band dies at 66May 1, 2025 | msn.comMike Peters Dies: The Alarm’s Frontman Was 66May 1, 2025 | msn.comThey Can’t Rain on Her ParadeApril 14, 2025 | capemaycountyherald.comToronto runners brave rain to raise roughly $23,000 for cancer fightMarch 15, 2025 | msn.com13-year-old rain cancer survivor calls out Democrats: ‘Stop being mean to Trump’March 8, 2025 | msn.comBrain cancer: Recognising tumour symptoms, risk factors and seeking treatmentNovember 24, 2024 | msn.comStars shine despite rain on Illinois’ Night of ChampionsNovember 15, 2024 | harnessracingupdate.comUI researcher wins $10 million dollars to combat ovarian cancerNovember 14, 2024 | kwwl.com'Smart freeway' to cut commute for thousands of Perth motoristsNovember 14, 2024 | 9news.com.auIcy spots possible Wednesday morning as temperatures fall below freezingNovember 13, 2024 | atlantic.ctvnews.caNewfoundland man electrocuted by downed power line, two women injuredNovember 11, 2024 | msn.comKing Charles III and Kate attend remembrance events as both slowly return to dutyNovember 11, 2024 | msn.comPrince William describes family's ‘brutal’ year as wife and father faced cancer treatmentNovember 8, 2024 | msn.comThe Eras Tour kept me going during my breast cancer treatmentNovember 8, 2024 | theglobeandmail.comSheila Jackson Lee’s daughter to finish her mother’s term before former Houston mayor takes 18th Congressional DistrictNovember 7, 2024 | click2houston.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNXTC, MEIP, RAIN, and BCEL Company DescriptionsAtreca NASDAQ:BCELAtreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.MEI Pharma NASDAQ:MEIP$2.28 +0.08 (+3.59%) Closing price 06/24/2025 03:50 PM EasternExtended Trading$2.30 +0.02 (+0.92%) As of 06/24/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.NextCure NASDAQ:NXTC$0.47 0.00 (-0.91%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$0.47 +0.01 (+1.78%) As of 06/24/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.Rain Enhancement Technologies Holdco NASDAQ:RAINAs of January 26, 2024, operates as a subsidiary of Pathos AI, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
